D&B Business Directory
Phio Pharmaceuticals Corp.
Overview
Phio
RXi Pharmaceuticals doesn't let bad genes stand between you and your health. The company specializes in developing drugs based on RNA interference (RNAi), which cuts off a gene's ability to produce a disease. The company believes its approach can lead to a whole new class of drugs for previously untreatable conditions. In 2011 RXi acquired late-stage drug developer Apthera and its leading oncology candiate NeuVax. Following that move, RXi changed ...
Read More
its name to Galena Biopharma. However, with two separate drug candidates, the two businesses never fully integrated and split apart in 2012. RXi Pharmaceuticals kept its RNAi-drug development business while Galena Biopharma took over NeuVax.
Read Less
Robert J Bitterman   See more contacts
?
?
Modelled

?
Actual
$5 DEC
? ?
NASDAQ:PHIO
Contacts
Get in Touch with 2 Principals* and 15 Contacts
D&B Hoovers Logo

Dynamic search and list-building capabilities

Real-time trigger alerts

Comprehensive company profiles

Valuable research and technology reports

Stay on top of your Business Credit File
Get full access to view your D&B business credit file now for just $39/month!
View D&B Scores & Ratings